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"Strict" blood pressure control and progression of renal disease in
hypertensive nephrosclerosis. Hypertensive nephrosclerosis is a progres-
sive renal disease and the leading cause of end-stage renal disease
(ESRD) in blacks in the United States. It is generally believed that
hypertensive renal injury is responsible for progressive renal failure;
however, it is not known whether pharmacologic lowering of blood
pressure to any level prevents progression of renal disease. Accordingly,
we performed a long-term prospective randomized trial to determine
whether "strict" [diastolic blood pressure (DBP) 65 to 80 mm Hg] versus
"conventional" (DBP 85 to 95 mm Hg) blood pressure control is
associated with a slower rate of decline in glomerular filtration rate.
Eighty-seven non-diabetic patients (age 25 to 73; 68 black, 58 male) with
long-standing hypertension (DBP  95 mm Hg), chronic renal insuffi-
ciency (GFR 70 m/min/1.73 m2) and a normal urine sediment were
studied. DBP was pharmacologically lowered to  80 mm Hg (3 of 4
consecutive measurements at 1 to 4 weeks intervals) after which patients
were randomized. DBP and GFR (renal clearance of 1251-iothalamate)
were measured at baseline, at three months and every six months
post-randomization. The rate of decline in GFR (GFR slope, in mi/mini
1.73 m2/year), estimated by the method of maximum likelihood in a mixed
effects model, was the primary outcome variable. In a secondary analysis,
50% reduction in GFR (or a doubling of serum creatinine) from baseline,
ESRD and death were combined. Also the rate of decline in GFR in
blacks and non-blacks was compared. Mean follow-up was 40.5 1.8
months in the "strict" and 42.2 2.1 month in the "conventional" groups.
Mean follow-up DBP was 81 1 mm Hg in the "strict" and 87 1 mm
Hg in the "conventional" groups (P < 0.0001, 95% C.I. for the difference
—8.4 to —3.1). GFR slope was —0.31 0.45 in the "strict" and —0.050
0.50mliminil.73 m2iyear in the "conventional" group (P> 0.25, 95% CI.
for the difference —1.60 to 1.08). The mean slopes were not significantly
different from zero. Twelve (7 with ESRD) of 42 "strict" and 7 (2 with
ESRD) of 35 "conventional" (2 ESRD) patients experienced a clinical
endpoint in the time to event analysis (P > 0.25). Mean follow-up DBP
was 85 1 in blacks and 79 1 in non-blacks (P < 0.01, 95% CI. 2.3 to
9.8); however, GFR slope in blacks (N = 58) was —0.016 0.37 versus
—0.27 0.76 mlimin/1.73 m2/year in non-blacks (P> 0.25). We conclude
that in hypertensive nephrosclerosis "strict" control of blood pressure to a
mean DBP of 81 0.8 mm Hg did not conserve renal function better than
"conventional" control of blood pressure to a mean of 86.7 1.1 mm Hg.
However, both "strict" and "conventional" blood pressure control are
associated with a very slow overall mean rate of decline in GFR. In
addition, we found that long-term blood pressure lowering was associated
with a similar slow rate of decline in GFR in blacks and non-blacks.
Application of this quality of blood pressure control could significantly
reduce the incidence of ESRD in the United States.
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Hypertensive nephrosclerosis is a progressive renal disease, and
the leading cause of end-stage renal disease (ESRD) in blacks [1,
2]. Prospective studies in predominantly black male populations
carried out in the 1950's and 1960's demonstrated that untreated
hypertension carries a substantial risk of ESRD [3, 41. Subsequent
studies in treated hypertensive nephrosclerosis indicated that
chronic renal insufficiency, that is, serum creatinine > 1.5 mg/dl,
is the most important risk factor for progressive renal damage in
hypertensive nephrosclerosis [3—6]. In addition, higher blood
pressure [3, 4, 7—9], black race [2, 5, 7, 10—13], male sex and older
age are all independently associated with increased risk for ESRD
[1, 5, 8, 11, 12, 14]. Moreover, these studies suggest that long-term
lowering of blood pressure in high-risk patients should preserve
renal function and lower ESRD risk.
In the early 1970's, bilateral nephrectomy became a standard
form of therapy for patients with severe refractory hypertension
and hypertensive nephrosclerosis [15]. Improved pharmacological
therapy, notably the introduction of minoxidil, eliminated the
need for this drastic procedure. In some cases treatment with
minoxidil reduced the rate of decay of renal function, prolonging
considerably the time interval to hemodialysis [16]. However,
nearly 1/3 of patients whose blood pressure was lowered to the
level of 160/100 continued to have declining renal function, and
far too many progressed to ESRD. The key question is to what
level should blood pressure be reduced to maintain renal function
in patients with hypertensive nephrosclerosis and established
renal insufficiency.
Lowering blood pressure in hypertensives has been shown to
reduce mortality due to stroke and myocardial infarction [3,
17—20], but the incidence of ESRD has increased [1, 2, 14, 21].
Furthermore, it has been suggested that lowering diastolic blood
pressure to  90 mm Hg protects the brain and heart, but not the
kidneys [22]. Studies performed in the 1950's and 1960's showed
that in comparison to placebo or untreated controls, pharmaco-
logic lowering of diastolic blood pressure to 95 to 100 mm Hg did
not preserve renal function [3, 4, 23]. Extremely high morbidity
and mortality rates precluded further placebo-controlled trials.
Subsequent studies in treated patients with mild to moderate
hypertension suggested that blood pressure lowering may pre-
serve renal function [5,8, 12, 16, 23, 24]. However, none of these
studies specifically examined the effect of long-term blood pres-
sure lowering on renal function. Moreover, no prospective study
has carefully delineated the rate of decline in renal function or
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rate of ESRD in treated patients with hypertensive nephrosclero-
sis. In a previous report from our institution, Pettinger et al
demonstrated that short-term "strict" followed by long-term
"conventional" control of diastolic blood pressure (DBP) in a
subset of 22 patients was associated with improvement in GFR
followed for 36 months [25]. We hypothesized that chronic
lowering of diastolic blood pressure to physiologic levels would
slow the decline in GFR to a greater extent than a higher but
"normal" level. Accordingly, we performed a long-term prospec-
tive randomized trial to determine whether "strict" (diastolic
blood pressure, DBP 65 to 80 mm Hg) versus "conventional"
(DBP 85 to 95 mm Hg) control of blood pressure is associated
with a slower rate of decline in GFR. To accomplish this, we
measured the rate of progression of renal disease in 87 patients
with hypertensive nephrosclerosis and reduced renal function by
serial measurement of GFR over an average period of 40 months.
Patients with renal insufficiency (Scr > 1.6 mgldl) were chosen
because of their high-risk for progressive renal disease [3—5, 26].
Methods
Patients
We recruited eighty-seven patients ranging in age from 25 to 73
with hypertensive nephrosclerosis. Patients were included in the
study if they had a diastolic blood pressure  95 mm Hg, a serum
creatinine of> 1.6 mg/dl and a GFR of  70 ml/min/1.73 m2, a
history of long-standing hypertension, an inactive urine sediment,
a protein excretion rate of 2 g/day, and no physical or
biochemical evidence for a humoral-mediated cause for hyperten-
sion. Patients with diabetes mellitus, a recent history (<4 months)
of malignant hypertension, stroke or myocardial infarction, acute
renal failure of any cause, analgesic abuse, polycystic kidney
disease, systemic lupus erythematosus, scleroderma, rapidly pro-
gressive glomerulonephritis, evidence of significant hepatic im-
pairment (AST and ALT greater than 2.5 x normal or serum total
bilirubin> 1.5 mg/dl), mental incapacity, pregnancy or lactation,
primary aldosteronism, renovascular hypertension, pheochromo-
cytoma, or a serum creatinine > 7.0 mgldl were excluded.
Demonstration of progression of renal disease prior to entry was
not required. The study was approved by the local Institutional
Review Board and written informed consent was obtained from
all participants.
Experimental design
Initial assessment period. Before randomization, DBP was low-
ered to 80 mm Hg over a three to six month initial assessment
period. To achieve this goal, participants were administered
antihypertensive medications using a stepped-care approach as
follows: (Step 1) diuretic; (Step 2) n-blocker; (Step 3) hydralazine
or minoxidil; and (Step 4) clonidine, a-methyldopa or r1-blocker.
In general the maximum dose of each agent (except diuretic) was
used before moving to the next step. Patients were considered
"responders" if on three of four consecutive clinic visits the DBP
was 80 mm Hg during this period. Based on this criterion, 77
patients were "responders" and 10 were "non-responders".
Randomization and intervention. The study was a 2 X 2 factorial,
randomized double-blind placebo-controlled trial. After comple-
tion of the initial assessment period, "responders" were random-
ized to either placebo or enalapril and to either "strict" 65 to 80
mm Hg and "conventional" 85 to 95 mm Hg blood pressure
ranges. These two ranges of DBP were chosen in an attempt to
achieve a mean difference of 10 mm Hg in DBP between groups
while maintaining DBP below 95 mm Hg in all patients. The lower
level of 65 to 80 mm Hg was chosen to emulate a "physiologic"
DBP level. Thus, in patients assigned to "conventional" group, we
allowed DBP to increase to the 85 to 95 mm Hg range whereas in
patients assigned to the "strict" group we attempted to maintain
DBP in the 65 to 80 mm Hg range. The 10 patients who did not
achieve the DBP goal of  80 mm Hg ("non-responders") were
not randomized but were followed-up with an attempt to maintain
DBP in the 85 to 95 range. Baseline characteristics for these
"non-responders" (data not shown) were similar and not signifi-
cantly different as compared to randomized patients. Because
assignment to enalapril versus placebo did not change the results
of the blood pressure control, this report describes the results of
blood pressure control only. Blood pressure medications were
titrated in the same manner in both placebo and enalapril treated
groups.
Follow-up procedures and measurements
Blood pressure controL Patients were followed at 12 week
intervals. Additional visits for blood pressure measurement and
medication adjustment were performed in an attempt to maintain
DBP in the assigned range throughout the follow-up period. After
randomization, 23 patients in the "strict" and 18 patients in the
"conventional" group received enalapril in addition to the
stepped-care antihypertensive regimen. The blinded study drug
was titrated to the maximum allowable dose and the unblinded
antihypertensive(s) were back-titrated as needed to achieve and
maintain blood pressure control. The titration procedure was
identical for both drug and blood pressure control arms of the
study. Compliance with the study medications was assessed at
each visit by patient interview and pill counting.
Measurement of blood pressure. Resting blood pressure was
measured after a minimum of five minutes in the supine position
using a standard mercury sphygmomanometer. The mean of three
measurements taken at two minute intervals was used for making
medication adjustments during baseline and post-randomization
periods. Systolic blood pressure (SBP) was determined as the
initial Korotkoff sound (phase I) and the DBP was determined at
the disappearance of Korotkoff sounds (phase V). Blood pressure
was measured on the day of the GFR in 90% of instances and
within one week of the GFR in all cases.
Measurement of renal function. Glomerular filtration rate and
serum creatinine were measured at the following specified inter-
vals: baseline (pre-randomization) and at 3, 9, 12, 18, 24, 36, 42,
48, 54 and 60 months post-randomization. Twenty-four hour urine
protein excretion rate was measured at six-month intervals during
follow-up. Serum and urine creatinine and urine protein concen-
trations were measured by automated methods (Smith, Kline and
Beecham Laboratories, Dallas, TX, USA).
GFR was measured by renal clearance of '251-iothalamate as
previously described [25, 271. Briefly, an oral water load of 20
ml/kg and 10 drops of saturated potassium iodide were adminis-
tered. After a minimum of 45 minutes, 35 j.Ci of 1251-iothalamate
was injected subcutaneously and the average of three 30-minute
urinary collections with midpoint blood samples was used to
calculate GFR. GFR was corrected for body surface area and
expressed in ml/min/1.73 m2. In our laboratory the intra-assay
coefficient of variation was 13 7%. The interassay coefficient of
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variation (3-month interval) for patients with GFR in the range of
25 to 70 ml/min/1.73 m2 was 12 4%.
Statistical methods and data analysis
Power calculations. During the planning phase of this trial the
baseline rate of decline in renal function for the "conventional"
group was unknown. The effect size was based on an expected
mean difference in the rate of decline in GFR of 4 mi/mm/year.
Using a standard deviation of 6 mI/mm/year, an a of 0.05, and a
power of 0.85 we calculated that 40 patients per group would be
required to detect this difference.
Measurement of change in renal function. The data were ana-
lyzed according to the principle of intention-to-treat. The rate of
decline in GFR (GFR slope in ml/minhl.73 m2/year) was the
primary outcome measure in this study. At least three GFR
measurements were considered necessary to calculate a valid
GFR slope and all patients met this criterion (mean = 7, range 3
to 11) [28]. The rate of decline in GFR for each group was
estimated by the method of maximum likelihood in a mixed effects
model which takes into account differences in duration of fol-
low-up among patients [29]. The estimated decline in GFR was
also calculated by the model after accounting for potential
predictors of declining GFR at baseline including age, race,
gender, serum creatinine and 24-hour urine protein excretion
rate. The data presented in Tables and Figures represent the
mean rate of change in GFR estimated by this method. In
addition, based on the experience of the Modification of Diet in
Renal Disease (MDRD) trial [30], we also evaluated the rate of
change in GFR using a piece-wise two-slope linear model in which
the effect of the first three months of (post-randomization)
intervention on the overall change in GFR within study groups
was evaluated. This piece-wise linear model estimates the slopes
from zero to three months (initial) and from three months until
the end of follow-up (terminal). The purpose of this analysis was
to assess whether the acute (first 3 months) effect of blood
pressure control results in differences in the magnitude and/or
direction of initial as compared to terminal GFR slope and how
such differences might affect overall slope. The mean of the
individual patient slopes over these periods of time were com-
puted as previously reported [30]. All GFR and Sr measurements
obtained at the intervals noted above were used in these calcula-
tions. Standard two-stage regression was performed on the rate of
decline in reciprocal of serum creatinine in which the slope was
estimated by least squares, and these slopes were treated as
outcome variables for mean, SOs, and t-tests.
Secondary analyses included comparison of GFR slope after
combining groups together, comparison of patients with baseline
24-hour urine protein rate > 500 mg versus < 500 mg and
comparison of black versus non-black patients. In the latter
comparison, GFR slope was calculated after adjusting for baseline
values (see above) as well as for differences in follow-up mean
blood pressure level. in addition, we performed a retrospective
combined time to event analysis to evaluate the impact of the
intervention on renal events and death. In this analysis, patient
demise was defined as the occurrence of any of the following:
doubling of serum creatinine from baseline, a 50% reduction of
GFR from baseline, ESRD, and death. ESRD was defined as
need for either dialysis or renal transplantation in patients with
symptomatic uremia and a GFR 15 ml/min/1.73 m2.
Student's t-test was used to test for differences between group
Table 1. Baseline characteristics of patients at randomization
Characteristic
Strict
(N = 42)
Conventional
(N = 35)
Entire group(N = 77)
Age years 55.8 1.5 55.7 1.6 55.7 1.1
Race black/non-black 29/13 29/6 58/19
Sex F/M 20/22C 9/26 29/48
Body mass index kg/rn2 28.9 0.9 28.2 1.0 28.7 0.7
Systolic BP mm Hg 124 2 122 3 123 2
Diastolic BPmm Hg 76 1 77 1 76 I
Mean arterial pressure 92 1 92 2 92 1
mm Hg
Serum creatinine mg/dl 2.5 0.2 2.1 0.1 2.3 0.1
Glomerular filtration rate 34.6 2.3 41.9 3.1 37.8 1.8
mi/mm/I. 73 rn2
Urine protein excretion rate 373 59 344 82 359 49
mg/day
Antihypertensive 2.7 0.2 2.6 0.2 2.7 0.1
medications (No.)"
Cardiovascular 14 14 28
complicationsc
a Strict vs. Conventional, P < 0.05 (Chi-square test)
Number of antihypertensive medications at baseline
C Previous cardiovascular complications including angina pectoris, myo-
cardial infarction, congestive heart failure and cerebrovascular accident.
means for specific variables and to determine whether individual
patient GFR slopes were different from zero. Ninety-five percent
confidence intervals for the differences in mean values were
calculated when appropriate. Fisher's exact test and Chi-square
test with Yates correction were used for comparison of nominal
data. In the time to event analysis, a Kaplan-Meier plot was
constructed and the data analyzed by log-rank test for differences
in survival times between randomized groups. A P value of < 0.05
or less was considered significant and all statistical analysis
employed two-tailed tests of significance. Data in tables are mean
SEM. There were no significant interactions between blood
pressure control groups and randomized drug group assignment,
that is, enalapril versus placebo and the rate of decline in GFR.
Therefore the results presented are confined to the effects of
blood pressure control groups on decline in GFR.
Results
Baseline characteristics
Baseline characteristics of 77 randomized patients at the time
of randomization are shown in Table 1. The majority of the
patients (53 of 77) had at least 36 months of follow-up. The
patients were predominantly black (75%), mostly male (63%) and
had a high rate (28 of 77) of cardiovascular complications prior to
randomization. The female-to-male ratio was significantly higher
in "strict" versus "conventional" patients. Baseline mean GFR
was slightly lower at 34.6 2.3 ml/min/1.73 m2 in the "strict" as
compared to 41.9 3.1 in the "conventional" group, however, this
difference was not statistically significant.
Follow-up
Primaiy analysis. The mean follow-up values for blood pressure,
renal function and outcome are shown in Table 2. Mean systolic
blood pressure was slightly lower in "strict" as compared with
"conventional" group but the difference was not significant (P =
0.11). In contrast, both mean DBP and mean MAP were signifi-
cantly lower in the "strict" group (Table 2). Mean DBP was 81±
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Table 2. Blood pressure control and renal function during follow-up in
hypertensive nephrosclerosis
Strict
Parameter (N = 42)
Conventional
(N = 35)
Entire group(N = 77)
Blood pressure
Systolic BP mm Hg 133 3 138 2 135 2
Diastolic BPmm Hg 81 1 87± P 84±1
Mean arterial pressure 98 1 104 1b 101 1
mm Hg
Renal function
Rate of decline in GFR —0.31 0.45 —0.05 0.50 —0.002 0.10
mI/mm/i. 73 m2/year
Rate of decline in 1/Sr —1.9 0.6
dI/mg/month x io—
—0.5 0.8 —1.4 0.6
Final serum creatinine 3.0 0.4 2.6 0.3 2.8 0.2
mg/dl
Change in serum creatinine 0.49 0.22 0.44 0.26 0.46 0.23
from baseline mg/dl
Event
50% decline in GFR or 4 5 9
doubled serum creatinine
(from baseline)
End-stage renal disease 7 2 9
Death 1 0 1
Total # 12 7 19
Duration of follow-up 40.5 1.8 42.2 2.1 41.3 1.6
months
Abbreviations are in Table 1. The rate of decline in GFR was estimated
by the method of maximal likelihood in a mixed effects model. The mean
value represents the best linear unbiased predictors of the rate of change
in GFR.
"P < 0.0001 compared with "strict" groupbP < 0.003 compared with "conventional" group
1 in the "strict" group and 87 1 mm Hg in the "conventional"
group. The mean difference for DBP was 5.7 mm Hg (P < 0.0001,
95% CI. —8.35 to —3.05) and for MAP was 5.5 mm Hg (P <
0.003, 95% C.!. —9.03 to —1.97). The mean rate of decline in
GFR for the "strict" group was —0.31 0.45 mlIminhl.73 m2/year
(range —1.73 to + 1.95) and for the "conventional" group was
—0.05 0.50 (range —2.32 to +3.09) ml/min/1.73 m2/year (Table
2, Fig. 1). The mean rate of decline in GFR for "strict" and
"conventional" groups were not significantly different from one
another. Neither rate of decline in GFR was significantly different
from zero (P> 0.25). The 95% confidence interval for the mean
difference in rate of decline in GFR was —1.60 to + 1.09. The rate
of decline in GFR estimated after running the model with
baseline age, race, sex, serum creatinine and 24-hour urine
protein excretion rate as covariates was —0.13 0.46 in the
"strict" group and +0.010 0.50 ml/min/1.73 m2/year (P> 0.25)
in the "conventional" group.
As shown in Figure 1, there was considerable variability in the
rate of change in GFR within groups; however, most patients
exhibited either an improvement or only a slow decline in GFR( —1 mllmin/1.73 m2/year). The mean difference between initial
and final GFR in the "strict" group was —2.2 1.9 ml/min/1.73
m2/year and +1.5 2.8 ml/min/1.73 m2/year in the "convention-
al" group. The slightly positive mean difference in GFR in the
conventional group, despite a negative mean slope, probably
reflects the variability in duration of follow-up among study
patients.
It is known that "acute" changes in GFR may accompany
alterations in blood pressure during the immediate post-random-
Blood pressure control group
Fig. 1. Distribution of change in GFR estimated by the miced effects model
for blood pressure control groups. The individual patient slopes (open
symbols) represent the best linear unbiased predictors of the rate of
change in GFR. Closed symbols are mean SEM. The mean rate of
decline in GFR was not significantly different between groups.
ization period [28]. Therefore, we analyzed the change in GFR
over time by dividing the slope into two components: (1) an
"acute" slope of zero to three months and (2) a "chronic" slope
consisting of three months to end of follow-up (statistical analysis
under Methods section). As shown in Figure 2 the apparent
overall slower decline in GFR in the "conventional" group was
due in part to an increase in GFR during the first three months
followed by a trend toward a greater decline in GFR during the
remainder of follow-up. In contrast, in the "strict" group, GFR
increased only slightly during the first three months followed by a
much slower overall decline during the remainder of follow-up.
Table 3 illustrates the "acute", "chronic" and total rate of change
in GFR for the blood pressure control groups. There were no
significant differences between groups for the initial (0 to 3
months) or the terminal (3 months to end of follow-up) slopes.
However, as shown in the table, to some extent the acute effect of
blood pressure changes during the first three months altered the
overall slope of the GFR so that during the long-term, GFR
deteriorated at a slightly, although not significantly, greater rate in
the "conventional" group.
Secondaty analysis: "Strict" and "conventional" groups com-
bined. The overall mean rate of progression for both groups
combined was —0.008 0.25 ml/min/1.73 m2/year. This indicates
that the overall mean rate of decline in GFR for the population is
quite slow. However, the correlation between GFR slope and
mean follow-up blood pressure after controlling for baseline
predictors of progression including age, race, sex, baseline GFR
and baseline protein excretion rate was poor. The correlation
coefficient for this relationship for GFR slope and mean follow-up
diastolic blood pressure was 0.050 (P = 0.21). It should be noted
that the range of mean diastolic blood pressures over which the
regression is carried out is relatively narrow (65 to 90 mm Hg) and
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LI
0
4
3
2
1
0
—1 -
—2 -
—3 -
ELI
LI
LI
LIThELI
LI
Toto et al: BP and progression of nephrosclerosis 855
—6 0 6 12 18 24 30 36 42 48
Time, months
Fig. 2. Estimated rate of change in GFR (mixed effects model, Methods
section) for blood pressure control groups during follow-up. Symbols are: (S)
"conventional", (U) "strict" groups. The rate of change in GFR is fitted to
a two-slope piece-wise model as previously described [30]. There is a trend
for the decline in GFR after three months of follow-up to be slightly
slower in the "strict" group as compared to the "conventional" group,
however, the difference is not significant. The bars represent 95%
confidence intervals for GFR estimates.
that 75 of 77 patients had mean DBP values were at or below 95
mm Hg.
Combined endpoints
Four of 42 "strict" and five of 35 "conventional" patients
experienced either a 50% decline in GFR or a doubling of serum
creatinine during follow-up, and six of these patients developed
ESRD. Three patients developed ESRD without doubling creat-
mine or experiencing a 50% decline in GFR. As shown in Figure
3, there were no differences between groups in the time to event
analysis. Of the nine patients who developed ESRD, seven were in
the "strict" and two in the "conventional" group, an incidence
rate of about 4%/year (9 of 77 over 3½ years; Table 2). The
duration of follow-up in patients with ESRD averaged 33 four
months and ranged from 18 to 54 months. The incidence of ESRD
was not different between groups (P> 0.25). Baseline mean GFR
was 19.3 5.3 ml/min/1.73 m2 (range 9.7 to 54) in patients who
developed ESRD as compared to 39.6 5.4 ml/min/1.73 m2
patients who did not progress to ESRD (P < 0.001, 95% CI.
—36.3 to —14.9). However, mean systolic (136 2) and diastolic
(80 0.1) BP in ESRD patients were not significantly different
from non-ESRD patients. There was one death ("strict" group)
during the study.
Mean 1/Se. slope was —0.0019 0.0006 in the "strict" and
—0.0005 0.0008 in the "conventional" groups. These slopes
were not significantly different from each other or from zero
(Table 2).
Group
Rate of change in GFR ml/min/l.73 m2/year
Acute Chronic Total
Strict (N = 42) 1.4 8.7 —0.38 0.50 —0.31 0.45
Conventional (N = 35) 15.3 9.8 —0.60 0.55 —0.05 0.50
Proteinuria
We compared the rate of change in GFR in 17 patients with a
baseline 24-hour urine protein excretion rate of> 500 mg to that
of 60 patients whose baseline 24-hour urine protein excretion rate
was < 500 mg. Mean rate of decline in GFR in patients with
> 500 mg/day was —2.1 0.80 and in patients with <500 mg/day
was +0.28 0.35 ml/min/1.73 m2/year (P < 0.01, 95% C.1. for the
difference —3.94 to —0.82). There was a significant negative
correlation between GFR slope and baseline proteinuria in
patients with baseline protein excretion > 500 mg/day (r = 0.53,
P < 0.03).
Comparison of blood pressure control and rate of decline in GFR
in blacks versus non-blacks
Because of the reportedly higher risk for progressive renal
failure in black patients, we compared blood pressure control and
rate of decline in GFR slopes between races. Baseline and
follow-up blood pressure and renal function for blacks and
non-blacks is shown in Table 4. Baseline GFR and blood pressure
were similar. During follow-up blood pressure was well controlled
in both blacks and non-blacks; however, blacks had significantly
higher blood pressure as compared to non-blacks. The mean
difference in follow-up DBP between blacks and non-blacks was
6.4mm Hg (P < 0.0001, 95% C.I. 3.29 to 9.51) and for MAP it was
5.3 mm Hg (P < 0.01, 95% C.I. 1.1 to 9.5). Mean follow-up DBP
was 90 in 48 black and all 19 white patients and  95 mm Hg
in all 56 blacks. Mean rate of decline in GFR in blacks was —0.16
0.37 ml/min/1.73 m2/year and in non-blacks it was —0.27 0.76
ml/min/1.73 m2/year (P> 0.25). After including baseline age, sex,
serum creatinine, 24-hour urine protein and follow-up blood
pressure as covariates in the model, the mean rates of decline for
blacks was —0.04 0.38 and for non-blacks —0.12 0.78 (P >
0.25). These rates of decline in GFR were not significantly
different from zero. Still, seven of nine patients who progressed to
ESRD were black although the proportion of blacks developing
ESRD (7 of 58) was not significantly different compared to
non-blacks (2 of 19).
Patients not randomized
The 10 non-randomized patients were followed for a mean of
39 3 months. Nine of 10 were male and all were black. At
baseline, renal function was not different from the randomized
groups; the mean serum creatinine was 2.2 0.2 and mean GFR
37.3 6 ml/min/1.73 m2. As expected, baseline diastolic blood
pressure (86 2.5 mm Hg) was significantly higher in non-
randomized patients compared to randomized patients (P <
0.03). Mean follow-up systolic blood pressure was 143 3.8 and
Table 3. Rate of change in GFR from 0 to 3 months ("acute slope"), 3
months to end of study ("chronic slope"), and from 0 to end of study
("total slope")
60
E55
. 50
E
a)_ 45
40
35
30
25
Mean rate of change in GFR (GFR slope) is calculated using the
method of maximal likelihood in a mixed effects model. There were no
significant differences in GFR slopes between groups.
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Randomization
Systolic BP mm Hg
Diastolic BP mm Hg
Mean arterial pressure
mm Hg
Serum creatinine mg/di
GFR mi/mini]. 73 m2
Follow-up
Systolic BP mm Hg
Diastolic BP mm Hg
Mean arterial pressure
mm Hg
GFR mm Hg
Rate of decline in GFR
mi/mini]. 73 m2/year
115C. slope
Serum creatinine final
Change in serum creatinine
mgidi (initial-final)
ESRD
Duration of follow-up
Units and abbreviations are the same as in Table 2. Mean rate of decline
in GFR was estimated by the method of maximal likelihood in a mixed
effects model.
P values: a < 0.0001; b < 0.01; C < 0.04
diastolic blood pressure was 91 1.2. Mean follow-up DBP was
not significantly different from the "conventional" group and
mean GFR slope was not significantly different from either
"strict" or "conventional" control groups. None of these patients
experienced a doubling of serum creatinine, a 50% decline in
GFR, ESRD or death.
Discussion
Chronic uncontrolled hypertension is believed to cause progres-
sive renal damage in patients with hypertensive nephrosclerosis.
Theoretically, long-term pharmacologic lowering of blood pres-
sure to normal should slow or halt progressive renal damage in
this condition. Previous prospective studies have been unable to
show a benefit of blood pressure lowering on progression of renal
disease in mild to moderate hypertensives [3—5, 7, 23]. However,
these studies were not specifically designed to examine the impact
of blood pressure control on renal function. Moreover, they did
not examine the impact of different levels of blood pressure
control on renal function and did not carefully evaluate the rate of
change in GFR in treated hypertensive nephrosclerosis.
The present study was designed to measure the decline in GFR
as a surrogate marker of progression of renal disease over a long
period of time. The purpose was to determine whether long-term
"strict" (65 to 80 mm Hg) versus "conventional" (85 to 95 mm
Hg) control of diastolic blood pressure is associated with a slower
decline in glomerular filtration rate in patients with hypertensive
nephrosclerosis and established renal insufficiency who are at
increased risk for disease progression [3—5, 26]. We found no
significant difference in the mean rate of decline in GFR between
"strict" and "conventional" blood pressure control groups despite
a significant difference of 5.7 mm Hg in mean follow-up DBP
(Table 2, Figs. 1 and 2). The mean rates of decline in GFR were
relatively slow in both groups. Moreover, as shown in Figure 1,
many patients in both groups appeared to have an improvement
or stabilization in GFR during the period of follow-up. Our data
_________ suggest that lowering blood pressure to the range of 81 to 87 mm
Hg in patients with mild to moderate renal insufficiency slows the
rate of development of ESRD due to hypertensive nephrosclero-
sis. Widespread application of this quality of blood pressure
reduction in hypertensive nephrosclerosis could dramatically re-
2.2 0.2 duce the incidence of ESRD in the United States.
38.5 4.0 Examination of the decline in GFR using the two slope model
indicated the effect of altering blood pressure control during the
133 first three months appeared to have an impact on the overall slope
97 2 during the trial (Fig. 2). Thus, the average decline in GFR in the
"conventional" group after the first three months was nearly twice
33.0 4.5 that of the "strict" slope during the same period (Table 3). This
0.27 0.76 observation suggests that patients assigned to the higher BP goal
—3 4 ÷ 20 had a somewhat better short-term outlook but perhaps a some-
3.0 0:6 what greater risk of ESRD in the long-term. Still, the mean rate
0.82 + 0.38 of decline in GFR after three months did not differ between
groups; however, the number of patients in the trial was small and
3 8 the variability in the GFR slope was considerable.— The fact that the mean difference in blood pressure was less
than our goal of 10 mm Hg reflects difficulty in maintaining
diastolic blood pressure below 80 mm Hg over a prolonged period
of time, particularly in individuals with hypertensive nephroscle-
rosis on multiple medications (Tables 1). Still, achieving a mean
DBP in the range of 81 mm Hg ("strict") or 87 mm Hg
("conventional") during periods up to 60 months was associated
with a slow mean rate of progression of renal failure in the
majority of patients with hypertensive nephrosclerosis (Figs. 1 and
2, Table 2). These rates are comparable to the rate of decline of
GFR with age as reported in normotensive white males over age
40 [31].
An important question is whether the power of this study was
too low to detect differences in the decline in GFR between blood
pressure control groups. At the time this study was designed, the
estimated mean difference in GFR between blood pressure inter-
vention groups was projected to be on the order of 4 ml/min/year.
It was calculated that approximately 80 patients would be needed
to detect this difference with an a error of 5% and a power of 0.85,
assuming a SD of about 6 mI/mm/year in GFR slope. Although we
observed that the variation in slope was in this range within both
groups, to our surprise the rate of decline in GFR in both groups
was much slower than expected. In other words the apparent low
power of our study to detect a difference resulted primarily from
the observed slow overall mean rate of decline in GFR even in the
"conventional" group (95% C.I. for the difference = —1.60 to
1.09). Therefore, the assumed mean rate of decline in GFR was
much larger than we observed. Although the power of the study is
relatively low, we believe it rather remarkable that renal function
deteriorated at such a slow mean rate in this study population.
Renal function was not preserved in all patients despite aggres-
sive blood pressure control (Table 2, Figs. 1 and 3). Furthermore,
renal failure progressed to ESRD in nine patients. Therefore, the
overall slow rate of decline in GFR is due, in part, to an
improvement in renal function in some patients that offset the
progressive decline in others (Fig. 1). Moreover, since there was
only a weak correlation between the rate of decline in GFR and
the mean follow-up blood pressure, these findings suggest that
Table 4. Blood pressure control and renal function at randomization
and during follow-up: Blacks versus non-blacks with hypertensive
nephrosclerosis
Black
(N = 58)
Non-black
(N = 19)
121 274 191 1
123 2
77 192 1
2.4 0.1
37.7 2.2
136 2C
85 1"
102 1b
38.8 2.8
—0.16 0.37
—0.6 0.5C
2.8 + 0.3
0.35 0.19
7
43.3 ÷ 1.7
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0 12 24 36 48 60
Strict 42 40 30 23 12 6
Conventional 35 34 30 24 9 3
Fig. 3. Kaplan-Meier plot of combined time-to-event analysis of outcome.
Symbols are: (_..........) "strict"; (...)"conventional" groups. The events
include doubling of serum creatinine, 50% reduction in GFR, ESRD or
death. Censored observations are denoted by vertical lines intersecting the
survival function at the point of censoring. The number of patients in each
group at each time point during follow-up is shown at the bottom of the
Figure. There were no significant differences in time to event between
groups.
other factors besides blood pressure control may be involved in
renal disease progression in these patients.
We did not study a contemporaneous placebo-treated control
group for comparison in view of the high rate of mortality in
untreated patients. However, the high prevalence of documented
non-renal cardiovascular complications prior to entry into the trial
(Table 1) and the extraordinarily high-risk for future complica-
tions in this study population precluded an untreated control
group on ethical grounds. Also, we did not measure the rate of
progression of renal failure in our patients prior to randomization;
therefore, we cannot prove that renal function would not have
progressed at similar rates in the absence of antihypertensive
therapy. However, to obtain such data prospectively would have
required an observation period of at least two years, and standard
medical care would have demanded controlling blood pressure at
a level similar to our "conventional" control group, that is,
diastolic blood pressure < 95 mm Hg.
We believe our patients would have progressed at an overall
faster rate with no treatment or with a less aggressive approach to
treatment. First, all our patients had reduced GFR, the most
important risk factor for declining renal function [5]. Second, our
patient population was composed of patients with characteristics
associated with increased risk of ESRD [1, 3, 4, 7, 9, 11, 16, 21, 23,
32, 331. Specifically, our study cohort had both a high prevalence
of end-organ damage at baseline and a high proportion of black
males (Table 1). In previous studies of hypertensive nephroscle-
rosis, GFR declined in 50 to 80% of untreated patients with
hypertensive nephrosclerosis [3, 4], a rate considerably higher
than that observed in the present study. Furthermore, the rate of
deterioration of GFR in untreated patients ranges from 3 to 12
ml/min/year [3, 4] and from 2.3 to 4.5 ml/min/year in treated
patients [30, 33, 34]. Moreover, in large studies of treated
hypertensives with impaired renal function at baseline, renal
function (estimated by Sr) deteriorates in 30% of white and 40%
of black patients [I• The mean rate of progression in these
reports is 4 to 6 times higher than the present study. Finally, the
incidence of ESRD in our population of patients with hyperten-
sive nephrosclerosis was 9 of 77, or about 12%. Over an average
period of 41 months, this computes to a rate of about 4% per year.
In comparison, the rate of ESRD in VA cooperative trial in
patients with poorly controlled hypertension and pre-existing
renal disease was 30% over three years or a rate of 10%/year [4,
26]. Unfortunately, we know of no other comparable patient
population screened and monitored during a similar period of
observation with which to compare our data.
Baseline GFR was significantly lower in patients who developed
ESRD as compared to those who did not. However, blood
pressure control and duration of follow-up were similar for ESRD
and non-ESRD patients. In addition, we found that patients with
higher grade proteinuria (that is, > 500 mg/24 hr) had a faster
decline in GFR, and the rate of decline was negatively correlated
with the magnitude of proteinuria. Taken together, these findings
suggest that long-term blood pressure control may not prevent
progression to ESRD when renal function is severely impaired.
Therefore, early detection and aggressive control of blood pres-
sure before a critical amount of renal mass and function are lost
may be extremely important in patients with hypertensive nephro-
sclerosis. Even though patients with apparently adequate control
progressed to ESRD, the time to develop ESRD may have been
prolonged because of aggressive blood pressure control. Further
studies in patients with lower baseline GFR are needed to
determine risk factors for progression.
Thirty-seven of 77 patients in this study were black males, a
group that is recognized to be at highest risk for ESRD due to
hypertension [1, 2, 4, 7, 12, 32]. Furthermore, seven of nine
instances of ESRD occurred in black (1 male/6 female) partici-
pants, consistent with previous reports that blacks are at higher
risk for ESRD. On the other hand, lowering diastolic pressure to
an average level of 85 mm Hg in blacks (Table 4) was associated
with stable or improved renal function in the majority of cases. It
is possible that with longer follow-up, renal function would
deteriorate significantly in these patients despite adequate blood
pressure control. Because the overall mean rate of progression is
slow, the results of this trial suggest that long periods (5 to 10
years) of follow-up should be employed in future studies focused
on this issue.
The observed overall slow mean rate of progression of renal
disease in patients at high risk for ESRD has not been reported
previously for any population of patients with advanced renal
disease. If confirmed, our observations have significant public
health implications. They could lead to a reduction in the
morbidity and mortality related to hypertension and to a reduc-
tion in health care costs [13]. Future treatments aimed at preven-
tion of ESRD should take these findings into account. In addition,
patient education programs designed to increase awareness may
be useful for early recognition and treatment of this disease.
1 •I -I
1.0
:
0.0
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In conclusion, in this long-term, prospective randomized clini-
cal trial of antihypertensive therapy in hypertensive nephroscle-
rosis, lowering diastolic blood pressure to a range of 81 to 87 mm
Hg in patients with hypertensive nephrosclerosis is associated with
stable or improving renal function in the majority of patients. The
observed rate of ESRD of 4%/year is considerably lower than
expected in untreated hypertensive nephrosclerosis [26]. More-
over, blacks of similar age, baseline renal function and long-term
blood pressure control exhibited a rate of loss of renal function
similar to non-blacks, suggesting that quality of blood pressure
control may be the basis for differences in the reported incidence
of ESRD between blacks and non-blacks. Our findings suggest
that the development of ESRD due to hypertensive nephroscle-
rosis can be slowed or prevented in most patients, particularly if
recognized and treated aggressively early in the disease process.
These results have important implications for design of future
trials and for delivery of health care in patients at high risk for
ESRD.
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